Answers are grounded in this paper and cite their sources.
The treatment landscape of advanced non-small cell lung cancer (NSCLC) has changed tremendously in the past 20 years, with the arrival of targeted therapies and immune checkpoint inhibitors (ICIs)1. Despite this success in the advance setting, the 5-year survival of operable NSCLC patients is only 80% for stage I and 13–60% for stages II and III1, so interest has reawakened in the synergy of chemotherapy, targeted therapies and ICIs in the adjuvant and neoadjuvant settings2,3. The latest version of the NCCN guidelines include nivolumab and platinum-doublet chemotherapy as neoadjuvant systemic therapy, and osimertinib and atezolizumab as adjuvant systemic therapies after adjuvant chemotherapy4.
No takes yet. Share an insight, caveat, or question.
Conde et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: